Pyrazinamide

Pyrazinamide is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please log in or purchase a subscription.

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

-- The first section of this topic is shown below --

General Principles

Pyrazinamide (15–30 mg/kg PO q24h [maximum, 2 g] or 50–75 mg/kg PO twice a week [maximum, 4 g/dose]) kills mycobacteria by an unknown disruption of membrane transport.
It is well absorbed orally and widely distributed throughout the body, including the CSF. Pyrazinamide is typically used for the first 2 months of therapy.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

General Principles

Pyrazinamide (15–30 mg/kg PO q24h [maximum, 2 g] or 50–75 mg/kg PO twice a week [maximum, 4 g/dose]) kills mycobacteria by an unknown disruption of membrane transport.
It is well absorbed orally and widely distributed throughout the body, including the CSF. Pyrazinamide is typically used for the first 2 months of therapy.

There's more to see -- the rest of this entry is available only to subscribers.